BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31164355)

  • 1. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
    Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
    Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
    Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
    Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNMT3A in Leukemia.
    Brunetti L; Gundry MC; Goodell MA
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
    Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
    Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
    J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
    Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
    Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.
    Kim SJ; Zhao H; Hardikar S; Singh AK; Goodell MA; Chen T
    Blood; 2013 Dec; 122(25):4086-9. PubMed ID: 24167195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
    Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
    Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
    Zhang X; Wang X; Wang XQD; Su J; Putluri N; Zhou T; Qu Y; Jeong M; Guzman A; Rosas C; Huang Y; Sreekumar A; Li W; Goodell MA
    Blood; 2020 Mar; 135(11):845-856. PubMed ID: 31932841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with DNMT3A mutations.
    Li Y; Zhu B
    Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
    Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
    J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A
    Chen D; Christopher M; Helton NM; Ferguson I; Ley TJ; Spencer DH
    Blood Cancer J; 2018 Apr; 8(4):38. PubMed ID: 29618788
    [No Abstract]   [Full Text] [Related]  

  • 16. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.
    Yang L; Rodriguez B; Mayle A; Park HJ; Lin X; Luo M; Jeong M; Curry CV; Kim SB; Ruau D; Zhang X; Zhou T; Zhou M; Rebel VI; Challen GA; Gottgens B; Lee JS; Rau R; Li W; Goodell MA
    Cancer Cell; 2016 Jun; 29(6):922-934. PubMed ID: 27300438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
    DiNardo CD; Patel KP; Garcia-Manero G; Luthra R; Pierce S; Borthakur G; Jabbour E; Kadia T; Pemmaraju N; Konopleva M; Faderl S; Cortes J; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2014 Aug; 55(8):1925-9. PubMed ID: 24138309
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
    Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
    Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.